Compare iShares MSCI Japan ETF (EWJ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI Japan ETF trades at $97.5 (market cap $24.21B), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: iShares MSCI Japan ETF is far larger — about 10.5× Recursion Pharmaceuticals Inc's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EWJ | RXRX | |
|---|---|---|
Market Cap | $24.21B | $2.31B |
Volume | 2,672,665 | 40,478,768 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $6.79 |
52-Week Low | $78.36 | $2.84 |
Typical Hold Time | 56 Days | 22 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $98.32, down 1.01% amid broader Asian market volatility. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $97 and resistance at $99. Recent news highlights Japan's monetary policy uncertainty as the BOJ navigates rate hikes and yen intervention efforts, creating both opportunities and risks for Japan-focused investors.
The outlook for EWJ remains cautiously optimistic given Japan's economic stimulus efforts and AI sector growth potential, though rising bond yields and currency volatility present significant headwinds. Investors should monitor BOJ policy decisions and yen stability as key catalysts for near-term performance.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
